Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study

Roderick C N Van Den Bergh, Hanna Vasarainen, Henk G. Van Der Poel, Jenneke J. Vis-Maters, John B. Rietbergen, Tom Pickles, Erik B. Cornel, Riccardo Valdagni, Joris J. Jaspars, John Van Der Hoeven, Frederic Staerman, Eric H G M Oomens, Antti Rannikko, Stijn Roemeling, Ewout W. Steyerberg, Monique J. Roobol, Fritz H. Schröder, Chris H. Bangma

Research output: Contribution to journalArticle

145 Citations (Scopus)

Abstract

Study Type - Therapy (prospective cohort) Level of Evidence 2b Objective To evaluate the short-term outcomes of the prospective international Prostate Cancer Research International: Active Surveillance ('PRIAS') study (Dutch Trial Register NTR1718), as active surveillance (AS) for early prostate cancer might provide a partial solution to the current overtreatment dilemma in this disease. Patients and methods The first 500 (of >950) participants with asymptomatic T1c/T2 prostate cancer, with a prostate-specific antigen (PSA) level of ≤10.0 ng/mL, a PSA density of 6 or more than two positive biopsy cores. There was a relatively unfavourable PSA doubling time of 0-10 years in 53% (102/194) and 62% (33/53) of men with favourable and unfavourable re-biopsy results, respectively. After RP, four of 24 (17%) men had T3 disease and 12 (50%) had a Gleason score of >6. Conclusion AS seems feasible, but mortality outcomes are unknown. A strict follow-up protocol including standard 1-year repeat biopsies resulted in a quarter of men stopping AS after 2 years.

Original languageEnglish
Pages (from-to)956-962
Number of pages7
JournalBJU International
Volume105
Issue number7
DOIs
Publication statusPublished - Apr 2010

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
Biopsy
Research
Neoplasm Grading
Mortality
Therapeutics

Keywords

  • Active surveillance
  • Biopsy
  • Outcomes
  • Prostate cancer
  • PSA
  • Watchful waiting

ASJC Scopus subject areas

  • Urology

Cite this

Van Den Bergh, R. C. N., Vasarainen, H., Van Der Poel, H. G., Vis-Maters, J. J., Rietbergen, J. B., Pickles, T., ... Bangma, C. H. (2010). Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study. BJU International, 105(7), 956-962. https://doi.org/10.1111/j.1464-410X.2009.08887.x

Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International : Active Surveillance' study. / Van Den Bergh, Roderick C N; Vasarainen, Hanna; Van Der Poel, Henk G.; Vis-Maters, Jenneke J.; Rietbergen, John B.; Pickles, Tom; Cornel, Erik B.; Valdagni, Riccardo; Jaspars, Joris J.; Van Der Hoeven, John; Staerman, Frederic; Oomens, Eric H G M; Rannikko, Antti; Roemeling, Stijn; Steyerberg, Ewout W.; Roobol, Monique J.; Schröder, Fritz H.; Bangma, Chris H.

In: BJU International, Vol. 105, No. 7, 04.2010, p. 956-962.

Research output: Contribution to journalArticle

Van Den Bergh, RCN, Vasarainen, H, Van Der Poel, HG, Vis-Maters, JJ, Rietbergen, JB, Pickles, T, Cornel, EB, Valdagni, R, Jaspars, JJ, Van Der Hoeven, J, Staerman, F, Oomens, EHGM, Rannikko, A, Roemeling, S, Steyerberg, EW, Roobol, MJ, Schröder, FH & Bangma, CH 2010, 'Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study', BJU International, vol. 105, no. 7, pp. 956-962. https://doi.org/10.1111/j.1464-410X.2009.08887.x
Van Den Bergh RCN, Vasarainen H, Van Der Poel HG, Vis-Maters JJ, Rietbergen JB, Pickles T et al. Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study. BJU International. 2010 Apr;105(7):956-962. https://doi.org/10.1111/j.1464-410X.2009.08887.x
Van Den Bergh, Roderick C N ; Vasarainen, Hanna ; Van Der Poel, Henk G. ; Vis-Maters, Jenneke J. ; Rietbergen, John B. ; Pickles, Tom ; Cornel, Erik B. ; Valdagni, Riccardo ; Jaspars, Joris J. ; Van Der Hoeven, John ; Staerman, Frederic ; Oomens, Eric H G M ; Rannikko, Antti ; Roemeling, Stijn ; Steyerberg, Ewout W. ; Roobol, Monique J. ; Schröder, Fritz H. ; Bangma, Chris H. / Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International : Active Surveillance' study. In: BJU International. 2010 ; Vol. 105, No. 7. pp. 956-962.
@article{0a8a6bda77104a9aa99e261b3e9a4523,
title = "Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study",
abstract = "Study Type - Therapy (prospective cohort) Level of Evidence 2b Objective To evaluate the short-term outcomes of the prospective international Prostate Cancer Research International: Active Surveillance ('PRIAS') study (Dutch Trial Register NTR1718), as active surveillance (AS) for early prostate cancer might provide a partial solution to the current overtreatment dilemma in this disease. Patients and methods The first 500 (of >950) participants with asymptomatic T1c/T2 prostate cancer, with a prostate-specific antigen (PSA) level of ≤10.0 ng/mL, a PSA density of 6 or more than two positive biopsy cores. There was a relatively unfavourable PSA doubling time of 0-10 years in 53{\%} (102/194) and 62{\%} (33/53) of men with favourable and unfavourable re-biopsy results, respectively. After RP, four of 24 (17{\%}) men had T3 disease and 12 (50{\%}) had a Gleason score of >6. Conclusion AS seems feasible, but mortality outcomes are unknown. A strict follow-up protocol including standard 1-year repeat biopsies resulted in a quarter of men stopping AS after 2 years.",
keywords = "Active surveillance, Biopsy, Outcomes, Prostate cancer, PSA, Watchful waiting",
author = "{Van Den Bergh}, {Roderick C N} and Hanna Vasarainen and {Van Der Poel}, {Henk G.} and Vis-Maters, {Jenneke J.} and Rietbergen, {John B.} and Tom Pickles and Cornel, {Erik B.} and Riccardo Valdagni and Jaspars, {Joris J.} and {Van Der Hoeven}, John and Frederic Staerman and Oomens, {Eric H G M} and Antti Rannikko and Stijn Roemeling and Steyerberg, {Ewout W.} and Roobol, {Monique J.} and Schr{\"o}der, {Fritz H.} and Bangma, {Chris H.}",
year = "2010",
month = "4",
doi = "10.1111/j.1464-410X.2009.08887.x",
language = "English",
volume = "105",
pages = "956--962",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "7",

}

TY - JOUR

T1 - Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International

T2 - Active Surveillance' study

AU - Van Den Bergh, Roderick C N

AU - Vasarainen, Hanna

AU - Van Der Poel, Henk G.

AU - Vis-Maters, Jenneke J.

AU - Rietbergen, John B.

AU - Pickles, Tom

AU - Cornel, Erik B.

AU - Valdagni, Riccardo

AU - Jaspars, Joris J.

AU - Van Der Hoeven, John

AU - Staerman, Frederic

AU - Oomens, Eric H G M

AU - Rannikko, Antti

AU - Roemeling, Stijn

AU - Steyerberg, Ewout W.

AU - Roobol, Monique J.

AU - Schröder, Fritz H.

AU - Bangma, Chris H.

PY - 2010/4

Y1 - 2010/4

N2 - Study Type - Therapy (prospective cohort) Level of Evidence 2b Objective To evaluate the short-term outcomes of the prospective international Prostate Cancer Research International: Active Surveillance ('PRIAS') study (Dutch Trial Register NTR1718), as active surveillance (AS) for early prostate cancer might provide a partial solution to the current overtreatment dilemma in this disease. Patients and methods The first 500 (of >950) participants with asymptomatic T1c/T2 prostate cancer, with a prostate-specific antigen (PSA) level of ≤10.0 ng/mL, a PSA density of 6 or more than two positive biopsy cores. There was a relatively unfavourable PSA doubling time of 0-10 years in 53% (102/194) and 62% (33/53) of men with favourable and unfavourable re-biopsy results, respectively. After RP, four of 24 (17%) men had T3 disease and 12 (50%) had a Gleason score of >6. Conclusion AS seems feasible, but mortality outcomes are unknown. A strict follow-up protocol including standard 1-year repeat biopsies resulted in a quarter of men stopping AS after 2 years.

AB - Study Type - Therapy (prospective cohort) Level of Evidence 2b Objective To evaluate the short-term outcomes of the prospective international Prostate Cancer Research International: Active Surveillance ('PRIAS') study (Dutch Trial Register NTR1718), as active surveillance (AS) for early prostate cancer might provide a partial solution to the current overtreatment dilemma in this disease. Patients and methods The first 500 (of >950) participants with asymptomatic T1c/T2 prostate cancer, with a prostate-specific antigen (PSA) level of ≤10.0 ng/mL, a PSA density of 6 or more than two positive biopsy cores. There was a relatively unfavourable PSA doubling time of 0-10 years in 53% (102/194) and 62% (33/53) of men with favourable and unfavourable re-biopsy results, respectively. After RP, four of 24 (17%) men had T3 disease and 12 (50%) had a Gleason score of >6. Conclusion AS seems feasible, but mortality outcomes are unknown. A strict follow-up protocol including standard 1-year repeat biopsies resulted in a quarter of men stopping AS after 2 years.

KW - Active surveillance

KW - Biopsy

KW - Outcomes

KW - Prostate cancer

KW - PSA

KW - Watchful waiting

UR - http://www.scopus.com/inward/record.url?scp=77749286517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77749286517&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2009.08887.x

DO - 10.1111/j.1464-410X.2009.08887.x

M3 - Article

C2 - 19817747

AN - SCOPUS:77749286517

VL - 105

SP - 956

EP - 962

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 7

ER -